The reimbursement for expensive medicines: stakeholder perspectives on the SMA medicine nusinersen and the Dutch Coverage Lock policy

Féline E. V. Scheijmans, Margot L. Zomers, Sina Fadaei, Marthe R. Onrust, Rieke van der Graaf, Johannes J. M. van Delden, W. Ludo van der Pol & Ghislaine J. M. W. van Thiel
Abstract Background The reimbursement for expensive medicines poses a growing challenge to healthcare worldwide. In order to increase its control over the costs of medicines, the Dutch government introduced the Coverage Lock (CL) policy in 2015. The CL postpones decisions regarding reimbursement of expensive medicines until detailed advice on i.e., cost-effectiveness has been given. The CL has been in place for six years, has raised many questions and concerns, but currently, no evaluation is known...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.